TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells
Authors:
- 9 August 2012
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 20 (5) , 504-513
Abstract
We previously reported a method to generate dendritic cell (DC)-like antigen-presenting cells (APC) from human induced pluripotent stem (iPS) cells. However, the method is relatively complicated and laborious. In the current study, we attempted to establish a method through which we could obtain a large number of functional APC with a simple procedure. We transduced iPS cell-derived CD11b+ myeloid cells with genes associated with proliferative or anti-senescence effects, enabling the cells to propagate for more than 4 months in a macrophage colony-stimulating factor (M-CSF)-dependent manner while retaining their capacity to differentiate into functional APC. We named these iPS cell-derived proliferating myeloid cells ‘iPS-ML’, and the iPS-ML-derived APC ‘ML-DC’. In addition, we generated TAP2-deficient iPS cell clones by zinc finger nuclease-aided targeted gene disruption. TAP2-deficient iPS cells and iPS-ML avoided recognition by pre-activated allo-reactive CD8+ T cells. TAP2-deficient ML-DC expressing exogenously introduced HLA-A2 genes stimulated HLA-A2-restricted MART-1-specific CD8+ T cells obtained from HLA-A2-positive allogeneic donors, resulting in generation of MART-1-specific cytotoxic T lymphocyte (CTL) lines. TAP-deficient iPS-ML introduced with various HLA class I genes may serve as an unlimited source of APC for vaccination therapy. If administered into allogeneic patients, ML-DC with appropriate genetic modifications may survive long enough to stimulate antigen-specific CTL and, after that, be completely eliminated. Based on the present study, we propose an APC-producing system that is simple, safe and applicable to all patients irrespective of their HLA types.Keywords
This publication has 37 references indexed in Scilit:
- Dendritic cells in cancer immunotherapyEuropean Journal of Immunology, 2010
- Presentation of tumour antigens by dendritic cells and challenges facedCurrent Opinion in Immunology, 2010
- Dendritic cells as therapeutic agents against cancerFrontiers in Bioscience-Landmark, 2010
- Characterization of Dendritic Cells and Macrophages Generated by Directed Differentiation from Mouse Induced Pluripotent Stem CellsStem Cells, 2009
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Directed Differentiation of Human Embryonic Stem Cells into Functional Dendritic Cells through the Myeloid PathwayThe Journal of Immunology, 2006
- Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitroThe Lancet, 2004
- Generation and genetic modification of dendritic cells derived from mouse embryonic stem cellsBlood, 2003
- Directed differentiation of dendritic cells from mouse embryonic stem cellsCurrent Biology, 2000